Illumina Correlation Engine Version 2.4
Illumina has released its version 2.4 of its Correlation Engine software for interpreting results from omics studies by identifying correlations to a repository of processed datasets. The new version adds interactive heatmaps for gene-level meta-analyses of study signatures, as well as signature-level meta-analyses against knowledgebased gene sets. Enhancements also include the ability to visualize quality control plots for public studies spanning multiple data types.
Applied DNA Sciences Mpox Clade I and Clade II Testing Services
Applied DNA Sciences said this week that its wholly owned clinical laboratory subsidiary Applied DNA Clinical Labs (ADCL) has launched an expansion of its clinical testing services for the detection of mpox to include testing for clade I and clade II. ADCL's Linea Mpox Virus 1.0 Assay was previously approved as a laboratory-developed test for the detection of mpox clade II by the New York State Department of Health (NYSDOH) in September 2022. In August 2024, ADCL conducted additional validation testing showing the assay can also detect the genetic sequence of mpox clade I, which is the subject of the World Health Organization's (WHO) Aug. 14 declaration of a public health emergency of international concern. ADCL will provide the testing service from its CLEP-permitted, CLIA-certified molecular diagnostics laboratory in Stony Brook, New York.
Seegene Novaplex MPXV/OPXV Plus, HSV-1&2/VZV/MPXV Assays
Seegene has launched two new research-use-only PCR assays with enhanced ability to detect mpox clade I, which is currently associated with higher transmission and mortality rates than mpox clade II.
The Novaplex MPXV/OPXV plus Assay detects three targets that can cause mpox disease. Specifically, it detects orthopoxvirus (OPXV) and mpox virus (MPXV), and includes specific confirmation of MPXV clade I. The assay also meets the World Health Organization's target product profiles (TPPs) for mpox assays and aligns with preferred target analyte criteria for distinguishing between clades I and II.
The firm has also launched the Novaplex HSV-1&2/VZV/MPXV Assay to simultaneously detect MPXV, herpes simplex virus types 1 and 2, and varicella-zoster virus. This test also complies with TPPs issued by the WHO.
Cornerstone Genomics CodeExome
Cornerstone Genomics has launched the CodeExome platform to accelerate the discovery of genetic targets by providing researchers with extensive cross-species data. Tailored for genome scientists in academia, government, and private enterprise, the cloud-based platform enables users to explore genes, test hypotheses, and upload their own data for cross-referencing against Cornerstone Genomics' proprietary database.
EIT Oxford EIT Pathogena
EIT (Ellison Institute of Technology) Oxford, through its Pathogen Programme, has launched EIT Pathogena, a genomic analysis tool for Mycobacterium. Built on Oracle cloud technology, this bioinformatics pipeline enables the assembly, variant calling, and comprehensive analysis of pathogen sequences, offering insights into species identification, drug susceptibility prediction, and the detection of outbreak clusters, EIT Oxford said. The initial focus of the pipeline is Mycobacterium tuberculosis and non-TB mycobacteria. EIT Pathogena will soon be scaled to cover additional pathogens, including Escherichia coli, Shigella spp., Klebsiella spp., Salmonella spp., Staphylococcus aureus, Streptococcus pneumoniae, Neisseria gonorrhoeae, and Acinetobacter baumannii.
According to an EIT Oxford spokesperson, EIT Pathogena is currently free for all individual users in low- and middle-income countries (LMICs), or who are based in high-income countries (HICs) but are working with Mycobacterium samples collected from LMICs. Organizations based in HICs processing HIC samples will also be able to access the system for an extended free trial, the spokesperson said.
For more recently launched products and services, please visit the New Products page on our website.